Head-to-head evidence
Albuterol Sulfate (Provenetil-HFA) vs GW642444M
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
Albuterol Sulfate (Provenetil-HFA)
Marketed by Amphastar Pharmaceuticals, Inc.
NCT00634829 · Phase 3 · terminated
Proventil-HFA serves here as the active reference product against which the investigational albuterol-HFA is compared in a secondary analysis, while the trial's main comparison is between the investigational product and placebo; no results have been posted yet.
Next expected readout: April 2028 · NCT07426458 (registry estimate)
GW642444M
Developed by GlaxoSmithKline
NCT00600171 · Phase 2 · completed
The study was randomized and double-blind, compared five GW642444M doses with placebo, and included 614 randomized participants. Its primary lung-function endpoint was a surrogate measure rather than a direct clinical outcome, and the results were mixed across doses: the 12.5, 25, and 50 microgram doses outperformed placebo, while the 3 and 6.25 microgram doses did not.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Albuterol Sulfate (Provenetil-HFA)'s landscape · GW642444M's landscape